Not finding it? Sign in to also search OpenAlex live.
-
Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies2022 American Journal of Nephrology article Immunology and Microbiology Complement system in diseases Open access
Carla Nester, Gerald B. Appel, Andrew S. Bomback, Koenraad Peter Bouman, H. Terence Cook, Erica Daina, +14 more
70citations -
Management of recurrent C3 glomerulopathy after kidney transplantation2026 Nephrology Dialysis Transplantation article Immunology and Microbiology Complement system in diseases Open access
Hernando Trujillo, Teresa Cavero, Sarah Margaret Moran, Şafak Mirioğlu, Annette N. Bruchfeld, Stefanie Steiger, +7 more
0citations -
Plain Language Summary of PEGASUS, a Study Comparing Pegcetacoplan with Eculizumab for 16 Weeks in People with Paroxysmal Nocturnal Hemoglobinuria2023 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
0citations -
Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study)2024 Future Rare Diseases article Immunology and Microbiology Complement system in diseases Open access
Régis Peffault de Latour, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +10 more
0citations -
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access
Valérie F. Cosson, Rong Fu, Austin Gladston Kulasekararaj, Jun‐ichi Nishimura, Jens Panse, Alexander Röth, +14 more
10citations -
P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT
Jeff Szer, Jens Panse, Austin Gladston Kulasekararaj, Monika Oliver, Bruno Fattizzo, Jun‐ichi Nishimura, +3 more
1citations -
C1q binding to surface-bound IgG is stabilized by C1r 2 s 2 proteases2021 Proceedings of the National Academy of Sciences article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Seline A. Zwarthoff, Kevin Widmer, Annemarie Kuipers, Jürgen Strasser, Maartje Ruyken, Piet C. Aerts, +13 more
62citations -
Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria2021 New England Journal of Medicine article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent
Peter Hillmen, Jeff Szer, Ilene Ceil Weitz, Alexander Röth, Britta Höchsmann, Jens Panse, +11 more
407citations -
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access
Christopher Jordan Patriquin, Andrija D. Bogdanovic, Morag Griffin, Richard J. Kelly, Jaroslaw Pawel Maciejewski, Brian Patrick Mulherin, +9 more
20citations -
Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors2023 Clinical Pharmacology & Therapeutics article Immunology and Microbiology Complement system in diseases Open access
Jun‐ichi Nishimura, Antoine Soubret, Noriko Arase, Simon Buatois, Masaki Hotta, Jean‐Eric Charoin, +23 more
10citations -
Early Eculizumab Withdrawal in Patients With Atypical Hemolytic Uremic Syndrome in Native Kidneys Is Safe and Cost-Effective: Results of the CUREiHUS Study2022 Kidney International Reports article Immunology and Microbiology Complement system in diseases Open access
Romy N. Bouwmeester, Caroline Duineveld, Kioa Lente Wijnsma, Fréderike J. Bemelman, Joost W van der Heijden, Joanna A.E. van Wijk, +20 more
50citations -
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Austin Gladston Kulasekararaj, Anita Hill, Saskia M. C. Langemeijer, Richard A. Wells, Fernando Ataúlfo González Fernández, Anna Gayà, +12 more
36citations -
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study2022 Bone Marrow Transplantation article Immunology and Microbiology Complement system in diseases Open access
Peter Švec, Reem Elfeky, Jacques‐Emmanuel Galimard, Christine S. Higham, Arnaud Dalissier, Troy C. Quigg, +30 more
20citations